Gene therapy treatments
The company develops treatments for patients with rare neurological and metabolic diseases, based on clinically proven gene therapy technologies.
Source: LinkedIn company description · Retrieved October 13, 2026
Bloomsbury Genetic Therapies is a clinical-stage biotechnology company developing treatments for rare neurological and metabolic diseases.
The company was spun out of University College London and launched in October 2022 with funding from UCL Technology Fund.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company develops treatments for patients with rare neurological and metabolic diseases, based on clinically proven gene therapy technologies.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Snapshot: September 27, 2026
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 2, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 15, 2026, September 16, 2026, September 18, 2026, September 19, 2026, September 20, 2026, September 21, 2026, September 27, 2026, September 30, 2026 and October 8, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.